Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Presentation THT 2025

Impact of Barostim Therapy on Atrial Fibrillation Burden: A Retrospective Single-Center Study

Presenter: Hata Mujadzic

February 11, 2025

Presentation TCT 2024

TCT 466: Renal Artery Denervation Combined With Pulmonary Vein Isolation in Patients With Heart Failure and Atrial Fibrillation: A Randomized Trial Preliminary Results and Study Design

Presenter: Tomasz Skowerski

October 28, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Presentation Miami Valves 2023

Implementation of the shock team

Presenter: Rohan Goswami

February 02, 2023

Presentation THT 2022

The Effect of Rhythm vs. Rate Control for Atrial Fibrillation on Mortality and Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction: Updated Meta-Analysis

Presenter: Mohammed Al-Sadawi

February 01, 2022

Presentation Controversies and Advances 2021

Role of Digoxin in Heart Failure and Atrial Fibrillation

Presenter: Michelle M. Kittleson

December 03, 2021

Presentation Controversies and Advances 2021

In Defense of Digoxin

Presenter: John Mandrola

December 03, 2021

Presentation TCT 2019

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Presenter: Felix Mahfoud

September 27, 2019

Presentation AHA 2018

REDUCE-IT Trial: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L Bhatt

November 16, 2018

Presentation SWVS 2017

Atrial Fibrillation After SAVR: Optimizing management of peri-TAVR AF

Presenter: Ankur Kalra

May 06, 2017

Presentation TCT 2012

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Presenter: William Cohn

October 24, 2012

Presentation TCT 2012

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

Presenter: Peter Brady

October 23, 2012

Advertisement

Impact of Barostim Therapy on Atrial Fibrillation Burden: A Retrospective Single-Center Study

TCT 466: Renal Artery Denervation Combined With Pulmonary Vein Isolation in Patients With Heart Failure and Atrial Fibrillation: A Randomized Trial Preliminary Results and Study Design

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Implementation of the shock team

The Effect of Rhythm vs. Rate Control for Atrial Fibrillation on Mortality and Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction: Updated Meta-Analysis

Role of Digoxin in Heart Failure and Atrial Fibrillation

In Defense of Digoxin

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

REDUCE-IT Trial: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Atrial Fibrillation After SAVR: Optimizing management of peri-TAVR AF

Lone Surgical Treatment of Atrial Fibrillation: Meaningful Progress in the Past 15 Years?

Atrial Fibrillation:
1. CHADS2 vs. CHA2DS2-VASc Risk Assessment.
2. AHA/ACC vs. ACCP/ESC Approach to Stroke Prevention.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content